JP2007284433A5 - - Google Patents

Download PDF

Info

Publication number
JP2007284433A5
JP2007284433A5 JP2007073396A JP2007073396A JP2007284433A5 JP 2007284433 A5 JP2007284433 A5 JP 2007284433A5 JP 2007073396 A JP2007073396 A JP 2007073396A JP 2007073396 A JP2007073396 A JP 2007073396A JP 2007284433 A5 JP2007284433 A5 JP 2007284433A5
Authority
JP
Japan
Prior art keywords
irbit
composition
composition according
vivo
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007073396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007284433A (ja
JP5146944B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2007073396A priority Critical patent/JP5146944B2/ja
Priority claimed from JP2007073396A external-priority patent/JP5146944B2/ja
Publication of JP2007284433A publication Critical patent/JP2007284433A/ja
Publication of JP2007284433A5 publication Critical patent/JP2007284433A5/ja
Application granted granted Critical
Publication of JP5146944B2 publication Critical patent/JP5146944B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2007073396A 2006-03-20 2007-03-20 Ｉｐ３受容体結合タンパク質による細胞内標的分子の制御 Expired - Fee Related JP5146944B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007073396A JP5146944B2 (ja) 2006-03-20 2007-03-20 Ｉｐ３受容体結合タンパク質による細胞内標的分子の制御

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006077607 2006-03-20
JP2006077607 2006-03-20
JP2007073396A JP5146944B2 (ja) 2006-03-20 2007-03-20 Ｉｐ３受容体結合タンパク質による細胞内標的分子の制御

Publications (3)

Publication Number Publication Date
JP2007284433A JP2007284433A (ja) 2007-11-01
JP2007284433A5 true JP2007284433A5 (enExample) 2010-05-06
JP5146944B2 JP5146944B2 (ja) 2013-02-20

Family

ID=38756539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007073396A Expired - Fee Related JP5146944B2 (ja) 2006-03-20 2007-03-20 Ｉｐ３受容体結合タンパク質による細胞内標的分子の制御

Country Status (1)

Country Link
JP (1) JP5146944B2 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP4219648B2 (ja) * 2002-10-11 2009-02-04 独立行政法人理化学研究所 新規ｉｐ３受容体結合タンパク質とｉｐ３指示薬
CA2503390A1 (en) * 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Similar Documents

Publication Publication Date Title
EP2826791A3 (en) Humanized anti-C5aR antibodies
NO20091235L (no) Antagonistiske humane lysspesifikke monoklonale antistoffer
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
NO20083793L (no) Antistoffer mot amyloid-beta peptid
BRPI0612273A2 (pt) anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade
GEP20166454B (en) Sclerostin binding agents
CL2013002062A1 (es) Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende: metodo de preparacion; y su uso para estimular la respuesta inmune.
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
JP2016527891A5 (enExample)
JP2013503205A5 (enExample)
BR112013017002A2 (pt) "proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas"
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EA200970810A1 (ru) Модифицированные полипептиды рецептора активина и их применение
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2062917A3 (en) Antibodies to erythropoietin receptor and uses thereof
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
AR074397A1 (es) Polipéptidos receptores de activina iib estabilizados y usos de los mismos
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
RU2019119609A (ru) Пептиды, способные реактивировать мутанты р53
WO2007084868A3 (en) Treatment of disorders by activation of the unfolded protein response
JP2009525046A5 (enExample)
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use